Integrin Receptor Antagonist [EPC] - N0000175775

Name: Table of NDC products with integrin receptor antagonist
Creator: U.S. Food & Drug Administration
License: https://creativecommons.org/licenses/by-nc-sa/4.0/

Pharmacologic Class Information

Pharmacologic Code	N0000175775
Pharmacologic Name	Integrin Receptor Antagonist
Pharmacologic Uses	integrin receptor antagonist
Pharmacologic Concept	Established Pharmacologic Classes - [EPC]
Pharmacologic Concept Description	An established pharmacologic class is a term or phrase that is scientifically valid and clinically meaningful according to the following definitions: A scientifically valid pharmacologic class is supported by documented and submitted empiric evidence showing that the drug's pharmacologic class is known, not theoretical, and relevant and specific to the indication. A clinically meaningful pharmacologic class term or phrase enhances the ability of professionals to understand physiologic effects related to the indication or to anticipate undesirable effects that may be associated with the drug or pharmacologic class.

NDC Products with Integrin Receptor Antagonist

The table contains 2 products whose active ingredient are classified under the same pharmacologic class Integrin Receptor Antagonist [EPC].

	NDC	Proprietary Name	Non-Proprietary Name	Dosage Form	Route Name	Company Name	Status
	64406-008	Tysabri	Non-Proprietary Name: Natalizumab	Injection	Intravenous	Biogen Inc.	ACTIVE
	64764-300	Entyvio	Non-Proprietary Name: Vedolizumab	Injection, Powder, Lyophilized, For Solution	Intravenous	Takeda Pharmaceuticals America, Inc.	ACTIVE